BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25339703)

  • 1. Renin-angiotensin system within the diabetic podocyte.
    Márquez E; Riera M; Pascual J; Soler MJ
    Am J Physiol Renal Physiol; 2015 Jan; 308(1):F1-10. PubMed ID: 25339703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose specifically regulates TRPC6 expression in the podocyte in an AngII-dependent manner.
    Sonneveld R; van der Vlag J; Baltissen MP; Verkaart SA; Wetzels JF; Berden JH; Hoenderop JG; Nijenhuis T
    Am J Pathol; 2014 Jun; 184(6):1715-26. PubMed ID: 24731445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of a local renin angiotensin system in podocytes by glucose.
    Durvasula RV; Shankland SJ
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F830-9. PubMed ID: 18216149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin inhibits the insulin-mediated ACE2 increase in cultured podocytes.
    Márquez E; Riera M; Pascual J; Soler MJ
    Am J Physiol Renal Physiol; 2014 Jun; 306(11):F1327-34. PubMed ID: 24671333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Abnormality of renin-angiotensin system in podocyte dysfunction in diabetic kidney disease].
    Shao DC; Lu LM
    Sheng Li Ke Xue Jin Zhan; 2011 Aug; 42(4):246-50. PubMed ID: 22066414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes.
    Campbell KN; Raij L; Mundel P
    Curr Diabetes Rev; 2011 Jan; 7(1):3-7. PubMed ID: 21067505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research into the glomerular podocyte--is it relevant to diabetic nephropathy?
    White KE
    Diabet Med; 2006 Jul; 23(7):715-9. PubMed ID: 16842474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical Model for Glucose Dependence of the Local Renin-Angiotensin System in Podocytes.
    Pilvankar MR; Higgins MA; Ford Versypt AN
    Bull Math Biol; 2018 Apr; 80(4):880-905. PubMed ID: 29520569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Mechanisms Involved in Intrarenal Renin-Angiotensin and Alternative Pathways in Diabetic Nephropathy - A Review.
    Bahreini E; Rezaei-Chianeh Y; Nabi-Afjadi M
    Rev Diabet Stud; 2021; 17(1):1-10. PubMed ID: 34289001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.
    Ziyadeh FN; Wolf G
    Curr Diabetes Rev; 2008 Feb; 4(1):39-45. PubMed ID: 18220694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The renin-angiotensin system.
    Lai KN; Leung JCK; Tang SCW
    Contrib Nephrol; 2011; 170():135-144. PubMed ID: 21659766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual effects of RAS blockade on blood pressure and podocyte function.
    Reiser J; Mundel P
    Curr Hypertens Rep; 2007 Nov; 9(5):403-8. PubMed ID: 18177588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of angiotensin II in diabetic nephropathy.
    Kennefick TM; Anderson S
    Semin Nephrol; 1997 Sep; 17(5):441-7. PubMed ID: 9316212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.
    Jourdan T; Szanda G; Rosenberg AZ; Tam J; Earley BJ; Godlewski G; Cinar R; Liu Z; Liu J; Ju C; Pacher P; Kunos G
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5420-8. PubMed ID: 25422468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL; Gleason BL
    Ann Pharmacother; 2004; 38(7-8):1278-82. PubMed ID: 15187210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of local and systemic angiotensin in diabetic renal disease.
    Anderson S
    Kidney Int Suppl; 1997 Dec; 63():S107-10. PubMed ID: 9407435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.